| Providence Hospital and Medical
Centers
April 2005 |
Monthly
Cystic Fibrosis Newsletter
Julie Feldman MPH RD, Clinical Dietitian |
| |
|
Back
Online
You may have been thinking, where is that CF newsletter that I so love to
read each month! Well, it has been on maternity leave. But we are happy
to publish the first, in a while, CF newsletter. Back and better than ever,
we promise to continue to keep you updated and abreast of all new information
that pertains to your health, along with other fun tidbits and of course
good recipes. If you have any questions about upcoming CF news or information
contained in this newsletter, please contact Julie at julbethy@yahoo.com. |
 |
| |
|
 |
Fast Track
PTC Therapeutics, a biopharmaceutical company, focused on the development
of drugs targeting DNA, has announced that the company has been granted
fast track designation from the United States Food and Drug Administration
(FDA) for the development of its novel drug, PTC124, for the treatment
of cystic fibrosis(CF). Development programs receiving fast track designations
typically receive FDA priority review (6-month vs. standard 10-month review).
PTC124 targets the nonsense mutation in the cystic fibrosis transmembrane
regulator (CFTR) gene. Nonsense mutations are single-point alterations
in the genetic code that prematurely halt the translation process, producing
a shortened, non-functional protein. PTC124 allows the cellular machinery
to bypass the nonsense mutation and continue the translation process, restoring
the production of full-length, functional proteins. It is estimated that
10% of the cases of cystic fibrosis (CF) and 15% of the cases of Duchenne
muscular dystrophy (DMD) are due to nonsense mutations. PTC has catalogued
over 1,800 distinct genetic disorders where nonsense mutations are the
cause of the disease in an appreciable percentage of patients. In addition
to CF and DMD, other potential indications under consideration for PTC124
include hemophilia, neurofibromatosis, retinitis pigmentosa, bullous Skin
diseases, and lysosomal storage disorders. |
| |
|
Technology a Cure
Alnylam and Cystic Fibrosis Foundation Therapeutics, announced on March 16,
2005 that they are developing RNA therapeutics, targeting the defective
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein, for
the potential treatment of cystic fibrosis. Under the agreement, the companies
will use Alnylam's RNA technology that restores protein function. |
 |
| |
|
 |
Speed Screening
Ambion Diagnostics, announced the adoption of its first molecular genetic
test test, Signature CF 2.0 ASR. The Signature CF 2.0 ASR detects mutations
in the gene associated with cystic fibrosis (CF), and represents a
new generation of molecular diagnostic tests that brings simplicity and
speed to genetic testing. Cystic Fibrosis is one of the most common genetic
disorders in Caucasian populations, carried by about 1 in 29 individuals.
CF is much less frequent in Asian Americans (carried by 1 in 90), in
African Americans (1 in 65), and in Hispanic Americans (1 in 46). The
American College of Obstetrics and Gynecology (ACOG) now recommends that
obstetrician-gynecologists make DNA screening for cystic fibrosis available
to all couples seeking preconception or prenatal care - not just those
with a personal or family history of carrying the CF gene, as previously
recommended. The Signature CF 2.0 ASR, can be used to identify 25 mutations
and 6 variants of the cystic fibrosis transmembrane conductance regulator
(CFTR) gene.
|
| |
|
CF Clinic Location
While most of you have been to our new office location,
many of our patients are always looking for our office as its location
changes frequently. We are currently located in Suite 203 of the Providence
Medical Building. Just take the elevator to the 2 nd floor, and turn
right . Our office is the first on the right. On that same note, if any
patients wish to be enrolled in the Axcan Scandipharm Comprehensive Care
Program which allows patients to receive free ADEK vitamins, flutter,
and Scandishakes with Ultrase prescription need to contact Julie at 248-464-0076. |
 |
| |
|
 |
Nutrition News
20 Minute Skillet Salmon
Fish is the perfect source of omega-3 fatty acids which help
reduce inflammation throughout the body. Enjoy this wonderful
Salmon Recipe for a delicious spring dinner.
Prep Time: 5 min
Total Time: 20 min
Makes: 4 servings
|
|
1 Tbsp. oil |
4 salmon fillets (about 4 oz. each) |
1 cup whole milk |
1/2 cup (1/2 of 8-oz. tub) PHILADELPHIA Cream Cheese
Spread |
1/2 cup chopped cucumber |
2 Tbsp. chopped fresh dill weed or 2 tsp. dried dill
weed |
|
|
HEAT oil in large skillet on medium-high
heat. Add salmon; cook 5 min. on each side or until fish
flakes easily with fork. Remove from skillet; cover with
foil. |
MIX milk and cream cheese spread
in skillet until well blended. Stir in cucumber and dill.
Return salmon to skillet. Cook 2 min. or until heated through. |
|
|
| All issues of Living
Your Best Life : |
May,
June,
Aug-Sept,
Oct,
Nov-Dec
2001
Jan,
Feb,
March,
April,
May,
Oct,
Nov
2002
Feb,
April,
May,
June,
Sept,
Oct,
Nov
2003
Jan,
Feb,
March,
April,
May,
Aug
2004
April, June,
July, Sept, Oct 2005
|
|
